Convergent Therapeutics
Radiopharmaceutical company developing targeted alpha therapy (TAT) for prostate cancer using PSMA-targeted actinium-225 conjugates.
Location
New York, New York, USA
Founded
2021
Investors
1
Categories
therapeutics, biotech, oncology, radiopharmaceuticals, prostate-cancer
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Novo Holdings | Hellerup, Denmark | biotech-focused | seedseries-a+3 | 13 |